Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252272 | 1.00 | ADRB1 (0.58) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL2250414 | 0.83 | ADRB1 (0.65) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL2873027 | 0.83 | ADRB1 (0.65) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL2873025 | 0.83 | ADRB1 (0.65) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL8534451 | 0.82 | ADRB1 (0.55) | ADRB1ALDH1A1HTR2C | |
| SCHEMBL27520825 | 0.75 | ADRB1 (0.55) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| SCHEMBL379449 | 0.75 | ADRB1 (1.00) | ADRB1DRD2KCNH2MAPTNPC1 | |
| SCHEMBL7838014 | 0.75 | ADRB1 (1.00) | ADRB1DRD2KCNH2MAPTNPC1 | |
| SCHEMBL28984332 | 0.74 | DRD2 (0.51) | ADRB1DRD2MTNR1AMTNR1BKCNH2 | |
| Hydrochloric Acid SCHEMBL8340614 | 0.74 | DRD2 (0.54) | ADRB1DRD2SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| CN-101087610-A | Arylpiperazine derivatives and their use as 5-HT1AUse of receptor ligands | SCHWARZ PHARMA S L (ES) | 2007-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | ADRB1 61/4885DRD2 214/4885MTNR1A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.